Pipeline

Our pipeline programs

Advancing a vaccine for the prevention of recurrent UTI, developing anticancer compounds, and compounds against the lung infections of cystic fibrosis patients

At Sequoia Vaccines, Inc., our initial focus is to conduct late state trials for our vaccine for the prevention of recurrent UTI.

Indication or Program Preclinical Phase 1 Phase 2 Phase 3 Market

SEQ-400

Recurrent Urinary Tract Infections

Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

SEQ-1274 drug platform

Ovarian and Other Cancers

Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started

Novel small molecule drug platform

Cystic Fibrosis Lung Infections

Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started

SEQ-400

A vaccine for recurrent urinary tract infections

Our lead program, SEQ-400 is a FimH vaccine that is being developed and evaluated for prevention of recurrent urinary tract infections (UTIs). A Phase 2/3 human study is set to begin in 2023.

About the recurrent UTI program

SEQ-1274 Drug Platform

For ovarian/other cancers

SEQ-1274 and analogs are small molecule inhibitors that are being developed as a potential treatment for patients with ovarian and other cancers.

Novel Small Molecule Drug Platform

For lung infections in cystic fibrosis patients

Analogs from a novel small molecule platform are undergoing optimization for inhibition of spreading bacterial biofilms that impact lung physiology of cystic fibrosis patients.

Research & publications

Sequoia’s research and development studies and programs have been published in more than 50 peer-reviewed scientific publications.

View publications